Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 2
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 1(1)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04217278Phase 2Active Not Recruiting

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Role: collaborator

NCT02411084Phase 3Terminated

Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD

Role: lead

NCT02724904Phase 1Withdrawn

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

Role: collaborator

All 3 trials loaded